1.    国家自然科学基金面上项目，DDR基因表达谱在肺癌术后预测及预后中的临床意义及应用研究

2.    国家自然科学基金青年基金，晚期肺腺癌基于代谢组学的化疗疗效预测模型建立及相关机制研究

3.    2022年黑龙江省“揭榜挂帅”科技攻关项目，恶性肿瘤筛查与早期诊断试剂盒研发

4.    中国医学科学院医学与健康科技创新工程（重大协同创新项目），KRAS突变型肿瘤的精细化分型及诊疗策略研究子课题：KRAS抑制剂的耐药机制、动态监测与应对策略

5.     国家肿瘤区域医疗中心科教培育基金——创新团队腾飞基金， 非小细胞肺癌免疫治疗生物标志物探索及治疗策略的优化

1.    Duan Jianchun, Wu L, Yang K, Zhao J, Zhao Y,Dai X, Li M, Xie Y, Yao Y, Zhao M, Zhou C, Ren X, Liu Z, Pan Y, Li Y, Liu B,Cheng Y, Miao L, Yu Q, Zhang Z, Liu X, Cui J, Zhang Y, Zhang L, Li X, Li X,Shen B, Chen B, Zeng S, Li B, Hu Y, Li L, Wu R, Song Q, Wang J. Safety,Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A inTreatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 InsertionMutations: A Phase 1 Trial. J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259-1.doi: 10.1016/j.jtho.2023.09.1449. 

2.     Duan J, Zhang Y, Chen R,Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, HuangR, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z. Tumor-immunemicroenvironment and NRF2 associate with clinical efficacy of PD-1 blockadecombined with chemotherapy in lung squamous cell carcinoma. Cell Rep Med. 2023Nov 28:101302. doi: 10.1016/j.xcrm.2023.101302. 

3.    Jianchun Duan, Longgang Cui,Xiaochen Zhao, et al. Use of Immunotherapy With Programmed Cell Death 1 vsProgrammed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A SystematicReview and Meta-analysis. JAMA Oncol. 2020 Mar 1;6(3):375-384. doi:10.1001/jamaoncol.2019.5367. 

4.    Zhijie Wang, JianchunDuan(equal contribution), Shangli Cai, et al. Assessment of bloodtumor mutational burden as a potential biomarker for immunotherapy in patientswith non-small cell lung cancer with use of a next-generation sequencing cancergene panel. JAMA Oncol. 2019; 5(5): 696-702. 

5.     Jianchun Duan, Jiachen Xu,Zhijie Wang, et al. Refined Stratification Based on Baseline ConcomitantMutations and Longitudinal Circulating Tumor DNA Monitoring in AdvancedEGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. J Thorac Oncol. 2020Dec;15(12):1857-1870. doi: 10.1016/j.jtho.2020.08.020. 

6.     Hua Bai#, JianchunDuan(equal contribution)# , Chengcheng Li # , WenzhuanXie # , Wenfeng Fang # , et al. EPHA mutation as apredictor of immunotherapeutic efficacy in lung adenocarcinoma. J ImmunotherCancer. 2020 Dec;8(2):e001315. doi: 10.1136/jitc-2020-001315. PMID: 33303576;PMCID: PMC7733211. 

7.     Zhijie Wang+, JianchunDuan(equal contribution)+, Guoqiang Wang+, et al. Allelefrequency-adjusted blood-based tumor mutational burden as a predictor of overallsurvival for non-small cell lung cancer patients treated with PD-1/PD-L1inhibitors. J Thorac Oncol. 2020 Apr;15(4):556-567., doi: 10.1016/ j. jtho.2019. 12. 001.

8.     Yiting Sun #, JianchunDuan #, Wenfeng Fang #, Zhijie Wang, Xinyang Du , Xin Wang ,Chengcheng Li , Shangli Cai , Jie Zhao , Sini Li , Li Zhang , Hua Bai , JieWang. Identification and validation of tissue or ctDNA PTPRD phosphatase domaindeleterious mutations as prognostic and predictive biomarkers for immunecheckpoint inhibitors in non-squamous NSCLC. BMC Med. 2021;19(1):239.Published 2021 Oct 7. doi:10.1186/s12916-021-02075-5  

9.     Jiefei Han, JianchunDuan, Hua Bai, et al. TCR repertoire diversity of peripheralPD-1+CD8+ T cells predicts clinical outcomes after immunotherapy in patientswith non-small cell lung cancer. Cancer Immunol Res. 2020 Jan;8(1):146-154.doi: 10.1158/2326-6066.CIR-19-0398.

10.   Zuo Y, Zhong J, Bai H, Xu B, Wang Z, Li W, Chen Y, Jin S, Wang S, Wang X,Wan R, Xu J, Fei K, Han J, Yang Z, Bao H, Shao Y, Ying J, Song Q*, Duan J*(Co-Correspondence),Wang J*. Genomic and epigenomic profiles distinguish pulmonary entericadenocarcinoma from lung metastatic colorectal cancer. EBioMedicine. 2022Aug;82:104165. doi: 10.1016/j.ebiom.2022.104165. Epub 2022 Jul 26. PMID:35901658; PMCID: PMC9334343.